Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in colorectal cancer
- Trial result
Colorectal cancer
ABFOLFOX (PD-L1 + VEGF + FOLFOX) drives immune-activated CRLM states, with 35% durable control
Atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) + leucovorin/5-FU/oxaliplatin (FOLFOX) was evaluated as neoadjuvant therapy for unresectable colorectal liver metastases (CRLM) in a prospectively registered cohort…
NCT03698461 - Trial result
Colorectal cancer
Ozekibart (INBRX-109) DR5 agonist + FOLFIRI delivers 23% ORR in 4L+ metastatic CRC
Ozekibart (INBRX-109) is a next-generation tetravalent death receptor 5 (DR5) agonist designed to induce tumor cell apoptosis; here it was combined with FOLFIRI in an open-label Phase 1 expansion cohort (C4d;…
NCT03715933 - Trial result
Colorectal cancer
Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
Ad5.F35-GUCY2C-PADRE is an off-the-shelf chimeric Ad5/35 vector vaccine targeting the intestinal tumor antigen GUCY2C and incorporating PADRE to enhance CD4+ help, designed to bypass pre-existing anti-Ad5…
NCT04111172 - Trial result
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) links early ctDNA clearance to longer survival in chemorefractory mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor, and panitumumab is an anti-EGFR monoclonal antibody; in the Phase 3 CodeBreaK 300 trial (NCT05198934) in chemorefractory KRAS G12C–mutant mCRC, this analysis tested…
NCT05198934 - Trial result
Colorectal cancer
ST316 β-Catenin/BCL9 Antagonist Reaches 46.7% ORR With 2L FOLFIRI/Bev in MSS mCRC
ST316 is a first-in-class IV peptide antagonist of the β-catenin–BCL9/9L interaction, designed to suppress oncogenic Wnt/β-catenin transcription while sparing physiologic Wnt signaling. In the ongoing Phase 1/2…
NCT05848739 - Trial result
Colorectal cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) c-Met–targeted topo-1 ADC posts 37% ORR in platinum-resistant ovarian cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) is a c-Met protein–targeting antibody–drug conjugate delivering a topoisomerase 1 inhibitor payload; in this Phase 1 open-label basket cohort (NCT06084481), patients with…
NCT06084481 - Trial result
Colorectal cancer
Leronlimab (CCR5 mAb) + TAS-102/Bev shows early ctDNA drops and 100% stable disease in refractory mCRC (CLOVER)
Leronlimab (LRM) is a subcutaneous anti-CCR5 humanized monoclonal antibody being added to the current late-line standard regimen trifluridine/tipiracil (TAS-102) plus bevacizumab in the open-label Phase 2 CLOVER…
NCT06699836 - Trial result Spotlight
Colorectal cancer
Ivonescimab (PD-1×VEGF bispecific) + mFOLFOX6 posts 70.8% ORR and 100% DCR in 1L unresectable mCRC (Phase 2)
Ivonescimab is an investigational tetrameric bispecific antibody co-targeting PD-1 and VEGF, here combined with oxaliplatin/5-FU/leucovorin (mFOLFOX6) as first-line therapy in a multiregional Phase 2 trial…
NCT05382442 - Trial result Spotlight
Colorectal cancer
Nivolumab + ipilimumab (PD-1 + CTLA-4) improves long-term treatment-free survival vs nivolumab in MSI-H/dMMR mCRC
Nivolumab + ipilimumab (NIVO + IPI), a dual immune checkpoint regimen targeting PD-1 and CTLA-4, was compared with nivolumab (PD-1) monotherapy in the Phase 3 CheckMate 8HW trial in metastatic colorectal cancer with…
NCT04008030 - Trial result Spotlight
Colorectal cancer
Tislelizumab (PD-1) neoadjuvant drives 78.6% pCR + ctDNA MRD clears fast in dMMR/MSI-H colon cancer
Tislelizumab is an anti–PD-1 monoclonal antibody engineered to minimize Fcγ receptor binding; here it was given as neoadjuvant monotherapy (200mg IV Q3W ×4, then up to 8+ cycles per MDT) with tumor-informed ctDNA MRD…
NCT06262581 - Trial result Spotlight
Colorectal cancer
Onvansertib (PLK1 inhibitor) + FOLFIRI/Bev lifts ORR to 72% and improves PFS signal in 1L RAS-mut mCRC
Onvansertib (Onv) is an oral, selective polo-like kinase 1 (PLK1) inhibitor combined here with standard doublet chemotherapy plus bevacizumab (FOLFIRI+Bev or FOLFOX+Bev) in the randomized Phase 2 CRDF-004 trial…
NCT06106308 - Trial result
Colorectal cancer
ABFOLFOX (PD-L1 + VEGF + FOLFOX) drives immune-activated CRLM states, with 35% durable control
Atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) + leucovorin/5-FU/oxaliplatin (FOLFOX) was evaluated as neoadjuvant therapy for unresectable colorectal liver metastases (CRLM) in a prospectively registered cohort…
NCT03698461 - Trial result
Colorectal cancer
Ozekibart (INBRX-109) DR5 agonist + FOLFIRI delivers 23% ORR in 4L+ metastatic CRC
Ozekibart (INBRX-109) is a next-generation tetravalent death receptor 5 (DR5) agonist designed to induce tumor cell apoptosis; here it was combined with FOLFIRI in an open-label Phase 1 expansion cohort (C4d;…
NCT03715933 - Trial result
Colorectal cancer
Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
Ad5.F35-GUCY2C-PADRE is an off-the-shelf chimeric Ad5/35 vector vaccine targeting the intestinal tumor antigen GUCY2C and incorporating PADRE to enhance CD4+ help, designed to bypass pre-existing anti-Ad5…
NCT04111172 - Trial result
Colorectal cancer
Zongertinib (selective irreversible HER2 TKI) drives 45% ORR with mostly grade 1 diarrhea in HER2+ CRC
Zongertinib is an irreversible, HER2-selective tyrosine kinase inhibitor designed to spare wild-type EGFR (aiming to reduce classic EGFR-TKI rash/diarrhea) and was evaluated as monotherapy in a pooled subgroup of…
NCT04886804 - Trial result
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) links early ctDNA clearance to longer survival in chemorefractory mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor, and panitumumab is an anti-EGFR monoclonal antibody; in the Phase 3 CodeBreaK 300 trial (NCT05198934) in chemorefractory KRAS G12C–mutant mCRC, this analysis tested…
NCT05198934 - Trial result
Colorectal cancer
ST316 β-Catenin/BCL9 Antagonist Reaches 46.7% ORR With 2L FOLFIRI/Bev in MSS mCRC
ST316 is a first-in-class IV peptide antagonist of the β-catenin–BCL9/9L interaction, designed to suppress oncogenic Wnt/β-catenin transcription while sparing physiologic Wnt signaling. In the ongoing Phase 1/2…
NCT05848739 - Trial result
Colorectal cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) c-Met–targeted topo-1 ADC posts 37% ORR in platinum-resistant ovarian cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) is a c-Met protein–targeting antibody–drug conjugate delivering a topoisomerase 1 inhibitor payload; in this Phase 1 open-label basket cohort (NCT06084481), patients with…
NCT06084481 - Trial result
Colorectal cancer
Leronlimab (CCR5 mAb) + TAS-102/Bev shows early ctDNA drops and 100% stable disease in refractory mCRC (CLOVER)
Leronlimab (LRM) is a subcutaneous anti-CCR5 humanized monoclonal antibody being added to the current late-line standard regimen trifluridine/tipiracil (TAS-102) plus bevacizumab in the open-label Phase 2 CLOVER…
NCT06699836 - Trial result
Colorectal cancer
ctDNA (MRD)-guided ACT (capecitabine±oxaliplatin) cuts 3-year recurrence in stage II MSS colon cancer
CIRCULATE (AIO KRK-0217/ABCSG; NCT04089631) used a tumor-informed NGS ctDNA assay post-op in stage II pMMR/MSS colon cancer: ctDNA+ patients were randomized to adjuvant chemotherapy (6 mo capecitabine or 3–6 mo…
NCT04089631 - Trial result
Colorectal cancer
EC (encorafenib+BRAF inhibitor) + cetuximab (EGFR mAb) + FOLFIRI cuts PFS risk ~56% in 1L BRAF V600E mCRC
Encorafenib (BRAF inhibitor) plus cetuximab (EGFR antibody) was combined with FOLFIRI chemotherapy as first-line treatment in BREAKWATER Cohort 3 (Phase 3, open-label; NCT04607421) for untreated BRAF V600E–mutant…
NCT04607421 - Trial result
Colorectal cancer
Lycopene (tomato-carotenoid) intake linked to ~40% lower recurrence/death risk in stage III colon cancer
In a prospective cohort nested within the Phase III CALGB (Alliance)/SWOG 80702 adjuvant trial (NCT01150045), post-diagnosis lycopene (a non–provitamin A carotenoid largely derived from tomato-based foods; diet ±…
NCT01150045 - Trial result
Colorectal cancer
Bevacizumab + FOLFOXIRI (VEGF blockade + triplet chemo) misses PFS bar vs bevacizumab doublets in right-sided mCRC
Bevacizumab (anti-VEGF antibody) plus FOLFOXIRI (5-FU/leucovorin, oxaliplatin, irinotecan) was tested against bevacizumab plus investigator’s choice FOLFOX/FOLFIRI as first-line therapy in the randomized, open-label…
NCT03641976 - Trial result
Colorectal cancer
AtezoTRIBE: ctDNA (ctF) non-responders show larger PFS gain with PD-L1 atezolizumab add-on in 1L mCRC
In the Phase 2 AtezoTRIBE trial (NCT03721653), adding the PD-L1 inhibitor atezolizumab to first-line FOLFOXIRI/bevacizumab in untreated metastatic colorectal cancer was evaluated here with a translational…
NCT03721653 - Trial result
Colorectal cancer
Nivolumab+ipilimumab (PD-1+CTLA-4) PFS benefit holds with single MSI PCR or MMR IHC CDx in MSI-H/dMMR mCRC
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) was evaluated in a post hoc CheckMate-8HW (Phase 3; NCT04008030) analysis asking whether central companion diagnostics (Idylla MSI PCR and/or Dako MMR…
NCT04008030 - Trial result
Colorectal cancer
Panitumumab (EGFR mAb) maintenance benefit holds regardless of baseline dNLR in RAS-WT mCRC—dNLR mainly prognostic for OS
Baseline derived neutrophil-to-lymphocyte ratio (dNLR; cut-off 2.2) was assessed post hoc in the PANAMA/AIO KRK0212 randomized Phase 2 trial (NCT01991873) of first-line RAS WT mCRC receiving FU/FA ± panitumumab…
NCT01991873 - Trial result
Colorectal cancer
Panitumumab (EGFR mAb) drives ctDNA “High→Low” conversions that track ~51–61mo OS in 1L mCRC
ctDNA dynamics were analyzed in PARADIGM (Phase 3; mFOLFOX6 + panitumumab vs mFOLFOX6 + bevacizumab) using paired baseline and post-treatment plasma from 556 patients with mCRC, stratified into High/Mid/Low ctDNA by…
NCT02394795 - Trial result
Colorectal cancer
Zanzalintinib (multi-kinase TAM/MET/VEGFR inhibitor) + atezolizumab (PD-L1) shows OS/PFS benefit—and atezo exposure appears to matter—in refractory mCRC
Zanzalintinib (zanza) is an oral multi-kinase inhibitor (TYRO3/AXL/MER, MET, VEGFRs) combined with atezolizumab (atezo), an anti–PD-L1 antibody, in the Phase 3 STELLAR-303 trial in previously treated metastatic CRC…
- New trial
Colorectal cancer
Phase 2 denikitug (GS-1811) trial tests CCR8-targeted Treg-depleting antibody in MSS CRC.
This Phase 2, open-label, multicenter, randomized study from Gilead Sciences evaluates denikitug (GS-1811), a CCR8-directed monoclonal antibody designed to target CCR8-expressing tumor-infiltrating regulatory T cells…
NCT07527858 Exploratory - New trial
Colorectal cancer
Phase 2b HRX215 (darizmetinib) MKK4 inhibitor to accelerate liver regeneration after PVE.
This Phase 2b, randomized, placebo-controlled study at Mayo Clinic tests whether HRX215 (darizmetinib)—an oral small-molecule inhibitor of MKK4 (MAP2K4)—can increase future liver remnant growth after portal vein…
NCT07612007 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.